Graves Adrienne L 4

4 · OCULAR THERAPEUTIX, INC · Filed Jun 12, 2026

AI-generated summary of this filing

Updated Jun 12, 2026

Ocular Therapeutix (OCUL) Director Adrienne Graves Receives Award

What Happened

Adrienne L. Graves, a director of Ocular Therapeutix, was granted equity awards on June 10, 2026: 14,000 shares (RSUs) and an additional 44,000 derivative share awards, for a total of 58,000 RSU-type units. Each was recorded at $0.00 per share (typical for restricted stock units), so the grant price shown is $0.00 and no cash changed hands at grant.

Key Details

Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (timely filing).
Reported acquisition: 14,000 RSUs (explicitly described in footnote F1) and 44,000 derivative awards (listed as acquired at $0.00).
Grant price/value: $0.00 per share on the Form 4 (RSUs are not purchases).
Shares owned after transaction: not specified in the provided excerpt of the filing.
Footnotes: F1 explains the 14,000 RSUs (each RSU equals one share) and F1/F2 describe that awards vest 100% on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting (vesting is conditioned on continued board service).
Filing timeliness: filed within two business days — not marked late.

Context

These are restricted stock units (derivative awards) that convert to actual shares only upon vesting; they are compensation, not an open‑market purchase or sale. Grants to directors are a common form of compensation and do not necessarily indicate immediate buying or selling intent.

Form 4

Period: 2026-06-10

Director

Transactions

Award
Common Stock
[F1]
2026-06-10+14,000→ 64,000 total
Award
Stock Option (Right to Buy)
[F2]
2026-06-10+44,000→ 44,000 total
Exercise: $8.74Exp: 2036-06-09→ Common Stock (44,000 underlying)

Footnotes (2)

[F1]On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
[F2]Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.

Signature

/s/ Todd Anderman, Attorney-in-Fact for Adrienne L. Graves|2026-06-12

1 file